# Claude Opus 4.8 / mol-d02

Original final answer, shared by both scoring rounds.

# Proposed Protocol: Testing p53-Necessity and Rescue-Specificity for Damage-Induced G1 Arrest

**All experiments described below are proposed, not performed.** Parameters marked "calibrate" must be determined empirically in the preparatory phase; I give calibration procedures rather than inventing values.

---

## 1. Conceptual framework and inference chain

**The claim to be tested** (from the fixed evidence packet): under defined DNA-damage conditions, functional p53 is *necessary* for G1 arrest, and acutely removing p53 abolishes that arrest while restoring near-endogenous p53 recovers it — all within one genetic background.

**Why the historical design is insufficient (the two curator-stated limits):**
1. *Different cell lines + pleiotropic drugs cannot prove same-background causation.* A line comparison confounds p53 with every other genetic/epigenetic difference, and caffeine affects many kinases. → Remedy: a single parental line with an acute, reversible p53 switch, so the only variable is p53 presence/absence at the moment of damage.
2. *Reduced DNA synthesis may reflect death or altered composition, not arrest.* A drop in bulk S-phase signal can arise if S-phase cells die preferentially, or if the population composition shifts. → Remedy: single-cell readouts (live-cell fate tracking + per-cell DNA content + per-cell nucleotide incorporation) plus explicit death quantification, so "arrest" is defined as *surviving cells that remain in G1 and do not incorporate nucleotide*, not as a bulk signal decline.

**Evidence → inference → conclusion logic:**
- *Evidence:* per-cell DNA content, nucleotide-incorporation status, live-cell fate, and death fraction, measured across four p53 states (endogenous, depleted, rescued, depleted+rescue-control) × two damage levels × ± caffeine.
- *Inference:* if G1 fraction rises and nucleotide incorporation falls **only when p53 is present**, and this is **restored by rescue**, and **death is matched across arms**, then the G1 accumulation is a genuine p53-dependent arrest rather than death/composition artifact.
- *Conclusion:* p53 is necessary under the tested damage load for the observed G1 arrest, and the rescue allele specifically restores it.

---

## 2. Isogenic system and the acute p53 switch

**Parental line:** one diploid, p53-wild-type, adherent line that is well-behaved for imaging and flow (calibrate choice by confirming a measurable baseline G1 arrest after damage in a pilot; e.g., a non-transformed epithelial or fibroblast line).

**Acute p53 depletion (preferred: degron, not chronic knockout).** Knock an auxin-inducible degron (AID2) or dTAG tag into the endogenous *TP53* locus (homozygous, both alleles tagged) so that adding the small-molecule degrader removes p53 protein within hours. Rationale: acute depletion avoids the clonal adaptation and compensatory rewiring that chronic knockouts accumulate, satisfying the "acute p53 loss" constraint and keeping background identical.

**Near-endogenous rescue.** Re-express an untagged (degrader-resistant) p53 cDNA from a single-copy, defined locus (e.g., safe-harbor landing pad) under a promoter titrated to **endogenous level**. Rescue specificity depends on near-physiological dose — overexpression can itself force arrest independent of damage and would confound the test.

- *Calibration of "near-endogenous":* quantitative immunoblot and single-cell immunofluorescence comparing rescue-allele p53 (in degraded background) against untreated parental p53. Accept a rescue clone whose basal and post-damage p53 abundance falls within a prespecified band (e.g., 0.5–2× endogenous; fix the band before selecting clones).

**Four engineered states (the p53 axis):**
| State | p53 locus | Degrader | Rescue allele |
|---|---|---|---|
| **P (endogenous)** | tagged | – | none |
| **D (depleted)** | tagged | + | none |
| **R (rescued)** | tagged | + | near-endogenous rescue |
| **C (rescue control)** | tagged | + | catalytically dead / DNA-binding-mutant p53 OR empty landing pad |

State C controls for the act of re-expressing *a* protein at the locus and for degrader off-target effects; a transactivation-dead p53 (e.g., DNA-binding-domain mutant) is the most stringent rescue control.

---

## 3. Independent units, replication, allocation, blinding

- **Independent unit = an independently seeded, independently treated well/dish**, processed as a separate biological replicate. Clone-level pseudo-replication (multiple wells from one passage counted as independent) is prohibited; count ≥3 independent passages/days per arm.
- **Engineering replication:** use ≥2 independently derived clones per engineered state (two degron clones, two rescue clones) to guard against clone-specific artifacts; treat clone as a random/blocking factor.
- **Allocation:** randomize well positions on plates (randomize across plate edges/center to break edge effects); randomize treatment order.
- **Blinding:** label samples with coded IDs so the analyst performing gating/segmentation/death scoring is blind to arm identity until after the prespecified pipeline is run. Keep a sealed key.

---

## 4. Calibrating the two perturbations

### 4.1 Damage agent and **matched damage load**
The identity/dose/timing are unspecified and must be calibrated. The critical requirement is that **the physical DNA-damage dose delivered to cells is matched across all p53 states**, so that any difference in arrest is attributable to p53 response, not to p53-dependent differences in damage uptake or repair-marker kinetics.

- *Choose an agent* producing a predominantly G1-relevant checkpoint response (e.g., IR or a radiomimetic for double-strand breaks, or UV — calibrate). Prefer an agent whose dose is physically controllable and p53-independent in delivery (IR dose is independent of cell state; drug uptake may differ — if a drug is used, verify intracellular dose).
- *Dose–response calibration:* in parental (P) cells, construct a dose series and pick **two damage levels**: a "low/moderate" dose giving measurable G1 arrest with low death, and a "higher" dose, to test dose-dependence. Fix doses before the main experiment.
- *Matched-load verification (independent of p53):* quantify a **p53-independent damage marker** per cell immediately after treatment across all four states — e.g., γH2AX foci or the comet assay at a fixed early time — to confirm equal initial lesion load in P, D, R, C. This directly addresses the confound that D cells might simply receive/retain different damage. Accept only if the early damage marker is statistically indistinguishable across states (prespecify equivalence margin).

### 4.2 Caffeine as a **separate perturbation** (not the primary test)
Caffeine is pleiotropic (it inhibits ATM/ATR among other targets); the historical limit explicitly flags that pleiotropic drugs cannot alone prove causation. Therefore caffeine is included as an **orthogonal perturbation of the damage-signaling pathway**, applied as its own factor, to test whether the upstream checkpoint is required for the p53-dependent arrest — **not** as the mechanism by which p53-necessity is established.

- *Calibration:* titrate caffeine in parental damaged cells to a dose that abrogates damage-induced G1 arrest without causing overt toxicity in the undamaged control (monitor death readout). Fix dose/timing (co-added with or just before damage — calibrate).
- *Interpretation guardrail:* caffeine effects are reported descriptively as a pathway perturbation; conclusions about p53-necessity rest on the degron/rescue axis, which is p53-specific.

### 4.3 Timing calibration
Damage-induced G1 arrest manifests over hours. Calibrate: (i) degrader pre-treatment duration to reach full p53 depletion (verify by immunoblot time-course); apply degrader long enough before damage that p53 is absent at damage onset in D/R/C. (ii) rescue allele must be present before damage. (iii) sampling times for fixed readouts: at least an early time (confirm damage, check pre-arrest) and a checkpoint time (peak expected G1 accumulation), plus a later time to detect escape/adaptation — calibrate from the live-cell data.

---

## 5. Measurements

### 5.1 Live-cell fate tracking (distinguishes arrest from death and from slow cycling)
Introduce a fluorescent cell-cycle reporter (e.g., PIP-degron/Cdt1-based G1 reporter, or a FUCCI-type two-color system) and a nuclear marker for segmentation, plus a live death indicator (see 5.3). Image at intervals (calibrate frame rate to track divisions without phototoxicity; verify division rate in untreated cells matches non-imaged controls to exclude phototoxic artifact).

Per-cell tracking yields, for each cell after damage: did it (a) remain in G1 without dividing (arrest), (b) progress through S and divide, or (c) die. **This single-cell fate assignment is the core defense against the death/composition confound**: it directly separates "did not synthesize DNA because arrested-and-alive" from "did not synthesize DNA because dead or dying."

### 5.2 Fixed DNA-content + nucleotide incorporation (per-cell, cross-sectional confirmation)
At fixed sampling times, pulse cells with a nucleotide analog (EdU) for a calibrated pulse window, then fix and stain DNA content (e.g., DAPI/PI) and EdU. Analyze by flow cytometry and/or quantitative imaging.

- **DNA content** → 2N (G1), 4N (G2/M), intermediate (S).
- **EdU** → active DNA synthesis (true S-phase), independent of DNA-content gating. The combination lets us classify: EdU⁻/2N = G1 (arrested if persisting), EdU⁺/intermediate = S, EdU⁻/4N = G2/M.
- Reporting **per-cell EdU positivity among live cells** (not bulk incorporation) addresses the "reduced DNA synthesis may reflect death/composition" limit directly: arrest = increased fraction of EdU-negative, 2N, *live* cells.

### 5.3 Death measurement (mandatory, concurrent)
Measure death in both modalities:
- *Live:* a real-time death dye (e.g., a cell-impermeant DNA dye marking membrane-compromised cells) co-imaged, so each tracked cell's death is time-stamped.
- *Fixed/flow:* viability dye + sub-2N (sub-G1) DNA content + an apoptosis marker (e.g., cleaved-caspase or Annexin-V) to quantify the death fraction at each sampling time.

Death must be reported for **every arm at every time**, because the only way to attribute a G1-fraction change to arrest is to show the death fraction is matched (or explicitly accounted for) across p53 states. If D cells die more in S-phase, that alone could inflate the apparent G1 fraction — the live-cell fate data plus sub-G1 quantification detect this.

### 5.4 Pathway/target confirmation
At a fixed post-damage time, measure a canonical p53 transcriptional target (e.g., p21/CDKN1A protein) per state to confirm functional p53 activity in P and R, its loss in D, and its absence with the transactivation-dead control C. This links the phenotype to p53 function, strengthening the inference beyond protein presence.

---

## 6. Prespecified gating (fix before unblinding)

Write and lock a gating SOP before data collection:
1. **Flow gating order:** singlets (area vs. width) → nucleated events → viability-dye-negative (**live gate**) → sub-G1 excluded and separately quantified → within live cells: DNA-content gates for G1 (2N±window), S, G2/M, calibrated on an **undamaged parental** reference each run. → EdU⁺/EdU⁻ threshold set on a no-EdU (unpulsed) control and an undamaged EdU⁺ control each run.
2. **Imaging segmentation:** fixed nuclear-segmentation parameters; tracking QC (minimum track length, exclusion of cells leaving the field or touching edges).
3. **Death call:** death-dye intensity threshold set on positive (permeabilized) and negative controls each run.
4. **"Arrested cell" operational definition:** a cell that is viability-dye-negative, 2N DNA content, EdU-negative, and (in live data) persists in G1 without division over the arrest window.

Compensation/controls run every session: unstained, single-stain, FMO controls; DNA-content doublet discrimination verified.

---

## 7. Primary contrast (prespecified, quantitative)

**Primary endpoint:** the **damage-induced G1-arrest index** = fraction of *live* cells that are EdU-negative and 2N, measured at the calibrated checkpoint time, in damaged minus undamaged (per arm, to isolate the damage-induced increment).

Define per arm:
ΔG1(arm) = [G1-arrest index | damage] − [G1-arrest index | no damage].

**Primary quantitative contrasts (two, both prespecified):**
1. **Necessity:** ΔG1(P) − ΔG1(D). Hypothesis: >0 (depleting p53 reduces damage-induced G1 arrest).
2. **Rescue specificity:** ΔG1(R) − ΔG1(D), and ΔG1(R) vs ΔG1(C). Hypothesis: ΔG1(R) significantly exceeds ΔG1(D) and approaches ΔG1(P), while ΔG1(C) remains at the D level.

A compact single statistic: a **rescue-recovery fraction** = [ΔG1(R) − ΔG1(D)] / [ΔG1(P) − ΔG1(D)], with 1.0 = full restoration. Prespecify a success band (e.g., recovery fraction ≥ 0.7 with CI excluding 0).

**Confirmatory (live-cell) contrast:** fraction of tracked live cells that arrest in G1 (no division over the window), same four-arm structure — must agree in direction with the fixed-cell primary contrast.

**Death-matching requirement:** report death fraction per arm; the primary contrast is interpreted as arrest only if death fractions are equivalent across P/D/R/C at matched damage (prespecify equivalence margin). If death differs, use the live-cell fate data to compute arrest among survivors and report an explicit sensitivity analysis.

---

## 8. Statistical analysis

- **Model:** mixed-effects model with fixed effects for p53 state, damage level, caffeine, and their interactions; random effects for clone and experimental day/batch. The necessity and rescue contrasts are prespecified linear combinations with multiplicity correction limited to the prespecified contrast family.
- **Effect sizes with CIs**, not p-values alone; report the recovery fraction with bootstrap CI.
- **Power/sample size:** calibrate from pilot variance of the G1-arrest index to size N (independent units) for the primary necessity contrast at target power (e.g., 80–90%); prespecify before the main run. Clone and day enter as blocking factors to recover power.
- **Equivalence tests** (TOST) for (i) matched damage marker across states and (ii) matched death across states.

---

## 9. Controls summary

| Control | Purpose |
|---|---|
| Undamaged, each p53 state | baseline G1/cycling; detect rescue-driven arrest independent of damage (overexpression artifact) |
| Degrader in parental untagged / tag-free locus check | degrader off-target effects |
| Transactivation-dead rescue (C) | re-expression/locus artifact; p53 function vs presence |
| Early γH2AX/comet across states | **matched damage load** |
| p21/target readout | confirms functional p53 activity ties to phenotype |
| No-EdU and undamaged-EdU⁺ | EdU gating |
| Viability/death stains every run | death quantification & sub-G1 |
| Caffeine ± damage, parental | pathway perturbation calibration |
| Imaging vs non-imaged growth | phototoxicity QC |

---

## 10. Acceptance / stopping criteria

**Proceed to main experiment only if (QC gates):**
- Degron achieves full p53 depletion by damage onset (immunoblot).
- Rescue p53 within prespecified near-endogenous band; functional (p21 induction restored).
- Parental line shows reproducible, measurable damage-induced G1 arrest in pilot.
- Early damage marker equivalent across the four states at chosen doses.
- Imaging non-phototoxic (division rates match non-imaged).

**Primary success (necessity + rescue):**
- ΔG1(P) − ΔG1(D) > 0 with CI excluding 0; AND
- rescue recovery fraction ≥ prespecified band with CI excluding 0; AND
- ΔG1(C) not different from ΔG1(D); AND
- death fractions equivalent across arms (or arrest-among-survivors confirms the same pattern).

**Stopping rules:**
- Stop/revise if death is not matchable even at low damage (confound unresolvable at that dose → drop to lower dose or switch agent).
- Stop if rescue clones cannot reach near-endogenous expression (overexpression would invalidate the specificity claim).
- Prespecify an interim QC look only; no outcome-adaptive stopping that would inflate error on the primary contrast.

---

## 11. Troubleshooting (anticipated failure modes → calibration response)

- **D cells show residual G1 arrest.** Check for incomplete depletion (immunoblot/IF per cell); extend degrader pre-treatment; verify both alleles tagged. Residual arrest may also be p53-independent (e.g., a separate checkpoint) — interpret as incomplete necessity, report as such.
- **Rescue over-arrests even without damage.** Expression above band → retitrate promoter/copy number; this is an overexpression artifact, not rescue.
- **Death differs across arms.** Use live-cell fate to compute arrest among survivors; lower damage dose; report sensitivity analysis. Rising sub-G1 in D at high dose suggests death-driven apparent composition change — exactly the confound the design anticipates.
- **EdU signal weak/variable.** Recalibrate pulse length and concentration; set thresholds per run on controls.
- **γH2AX differs across states** (p53 can feed back on repair). If early lesion load (comet) is equal but marker kinetics differ, rely on the physical lesion assay for the matched-load claim and note the kinetic difference.
- **Caffeine toxicity confounds.** Lower dose; report caffeine strictly as descriptive pathway perturbation.
- **Clone-to-clone discordance.** The two-clone design flags this; discordance means clone-specific artifact, not p53 effect — do not pool; investigate.

---

## 12. Alternatives and limits of the proposed design

- **Degron vs. knockout:** acute degron is chosen to avoid chronic adaptation, but degrader off-target effects exist → controlled by state C and the degrader-in-untagged control.
- **Near-endogenous rescue dependence:** conclusions about rescue specificity hold only within the verified expression band; outside it the test is invalid (overexpression).
- **Caffeine's pleiotropy is unresolved by design** — intentionally kept secondary; it cannot by itself establish p53-necessity (the historical limit), which is why the degron/rescue axis carries the inference.
- **Single parental background** means the conclusion is about *that* background under *those* damage conditions; generalization to other cell types is not claimed (matches the historical limit that cell-line comparisons confound).
- **"G1 arrest" vs. slowed G1 progression:** the later live-cell sampling time distinguishes durable arrest from transient delay; report arrest duration, not just a snapshot.
- **Matched-load claim** rests on the chosen damage marker faithfully reflecting the biologically relevant lesion; using two independent damage assays (foci + comet) hedges this.
- Residual p53-independent G1 control, if present, would cap the measured necessity effect; the design detects and quantifies rather than assumes complete necessity.

---

### One-paragraph summary
Build one isogenic line with an endogenous-tagged, acutely degradable p53 and a near-endogenous degrader-resistant rescue allele, plus a transactivation-dead rescue control. Calibrate a DNA-damage agent to two doses and caffeine to a checkpoint-abrogating dose, verifying **matched physical damage load** across all p53 states with a p53-independent lesion assay. Track single-cell fate live (arrest vs. division vs. death) and confirm cross-sectionally with per-cell DNA content + EdU among viable cells, quantifying death at every time. The prespecified primary contrasts — ΔG1(endogenous)−ΔG1(depleted) for necessity and the rescue-recovery fraction toward ΔG1(control) — establish whether p53 is necessary and specifically restored, while the live-cell fate data and death matching separate true G1 arrest from death or composition change. **All experiments are proposed.**
